Cystadenocarcinoma, Serous
"Cystadenocarcinoma, Serous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
MeSH Number(s)
C04.557.470.200.025.480.240
C04.557.470.590.480.240
Concept/Terms
Cystadenocarcinoma, Serous- Cystadenocarcinoma, Serous
- Cystadenocarcinomas, Serous
- Serous Cystadenocarcinoma
- Serous Cystadenocarcinomas
Below are MeSH descriptors whose meaning is more general than "Cystadenocarcinoma, Serous".
Below are MeSH descriptors whose meaning is more specific than "Cystadenocarcinoma, Serous".
This graph shows the total number of publications written about "Cystadenocarcinoma, Serous" by people in Harvard Catalyst Profiles by year, and whether "Cystadenocarcinoma, Serous" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 3 | 4 |
| 2004 | 3 | 0 | 3 |
| 2005 | 1 | 3 | 4 |
| 2006 | 2 | 1 | 3 |
| 2007 | 6 | 4 | 10 |
| 2008 | 10 | 1 | 11 |
| 2009 | 9 | 0 | 9 |
| 2010 | 10 | 3 | 13 |
| 2011 | 7 | 5 | 12 |
| 2012 | 10 | 1 | 11 |
| 2013 | 13 | 5 | 18 |
| 2014 | 9 | 1 | 10 |
| 2015 | 9 | 2 | 11 |
| 2016 | 8 | 4 | 12 |
| 2017 | 9 | 3 | 12 |
| 2018 | 10 | 0 | 10 |
| 2019 | 9 | 3 | 12 |
| 2020 | 13 | 4 | 17 |
| 2021 | 8 | 0 | 8 |
| 2022 | 8 | 0 | 8 |
| 2023 | 4 | 0 | 4 |
| 2024 | 3 | 0 | 3 |
Below are the most recent publications written about "Cystadenocarcinoma, Serous" by people in Profiles.
-
Norepinephrine induces anoikis resistance in high-grade serous ovarian cancer precursor cells. JCI Insight. 2024 Mar 08; 9(5).
-
Morphologic and Molecular Heterogeneity of High-grade Serous Carcinoma Precursor Lesions. Am J Surg Pathol. 2024 Apr 01; 48(4):475-486.
-
Validation and interpretation of Pan-TRK immunohistochemistry: a practical approach and challenges with interpretation. Diagn Pathol. 2024 Jan 10; 19(1):10.
-
Replication stress and defective checkpoints make fallopian tube epithelial cells putative drivers of high-grade serous ovarian cancer. Cell Rep. 2023 10 31; 42(10):113144.
-
Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer. Cell. 2023 08 03; 186(16):3476-3498.e35.
-
Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis. Can J Surg. 2023 May-Jun; 66(3):E310-E320.
-
Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States. Gynecol Oncol. 2023 08; 175:60-65.
-
CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study. Cancer. 2023 03 01; 129(5):697-713.
-
Clinical commentary: Extra-uterine high-grade serous carcinoma: two pathways, two preventions? Gynecol Oncol. 2023 02; 169:1-3.
-
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022. J Natl Compr Canc Netw. 2022 09; 20(9):972-980.